# Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

> **NCT02295475** · PHASE4 · COMPLETED · sponsor: **Scott C. Woller, MD** · enrollment: 48 (actual)

## Conditions studied

- Antiphospholipid Syndrome
- Thrombosis

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02295475
- **Lead sponsor:** Scott C. Woller, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-10
- **Primary completion:** 2020-04
- **Final completion:** 2022-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02295475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02295475, "Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02295475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*